Literature DB >> 16305985

The activation of ERK1/2 via a tyrosine kinase pathway attenuates trail-induced apoptosis in HeLa cells.

Myoung Woo Lee1, Jae Hyung Bach, Hyun Jung Lee, Do Yeon Lee, Wan Seok Joo, Yong Sik Kim, Soon Cheol Park, Kyung Yong Kim, Won Bok Lee, Sung Su Kim.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) serves as an extracellular signal that triggers apoptosis in tumor cells. To characterize the molecular events involved in TRAIL-induced apoptotic signaling, we investigated the role of extracellular signal-regulated kinase 1/2 (ERK1/2) in HeLa cell death. Here we show that TRAIL-activated ERK1/2 through a tyrosine kinase-dependent pathway, subsequently elevated anti-apoptotic Bcl-2 protein levels. ERK1/2 inhibition with PD98059 promoted apoptotic cell death through the downregulation of ERK1/2 activity and Bcl-2 protein levels. Moreover, tyrosine kinase inhibition with Genistein in TRAIL-induced apoptosis effectively attenuated ERK1/2 activity and enhanced apoptotic cell death. Taken together, our results indicate that ERK1/2 activation via tyrosine kinase pathway plays a protective role as the cellular defense mechanism through the upregulation of Bcl-2 protein levels in TRAIL-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305985     DOI: 10.1080/07357900500283036

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  7 in total

Review 1.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

2.  ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Kelly J Butnor; Harvey I Pass; Michele Carbone; Joseph R Testa; Nicholas H Heintz; Brooke T Mossman
Journal:  Int J Cancer       Date:  2011-01-06       Impact factor: 7.396

Review 3.  Multi-targeted therapy of cancer by genistein.

Authors:  Sanjeev Banerjee; Yiwei Li; Zhiwei Wang; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2008-05-19       Impact factor: 8.679

4.  pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.

Authors:  Ranadip Mandal; Monika Raab; Yves Matthess; Sven Becker; Rainald Knecht; Klaus Strebhardt
Journal:  Mol Oncol       Date:  2013-11-20       Impact factor: 6.603

5.  Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Mol Cancer       Date:  2010-12-15       Impact factor: 27.401

6.  The combination of TRAIL and isoflavones enhances apoptosis in cancer cells.

Authors:  Joanna Bronikowska; Ewelina Szliszka; Zenon P Czuba; Dariusz Zwolinski; Dariusz Szmydki; Wojciech Krol
Journal:  Molecules       Date:  2010-03-22       Impact factor: 4.411

7.  Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes.

Authors:  Deborah A Flusberg; Jérémie Roux; Sabrina L Spencer; Peter K Sorger
Journal:  Mol Biol Cell       Date:  2013-05-22       Impact factor: 4.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.